Acadia Pharmaceuticals

Researcher in lab
#Acadia Pharmaceuticals #Clinical trial #Phase III trial #Rare disease

Acadia cancels development of intranasal carbetocin in rare disease

Acadia Pharmaceuticals has announced that its Phase III COMPASS PWS trial evaluating intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS) did not meet its primary endpoint.  The treatment did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from… Read More

#News